Author:
Cheng Xianwen,Zhan Yanrong,Liu YaoShun,Zeng Xia,Wang Zhendong,Wang Feng,Mao Ya,Na Song
Abstract
AbstractThis study aims to observe the clinical efficacy of the dual plasma molecular adsorption exchange system (DPMAES) in patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF), with a focus on its regulatory effect on cytokine storm. A total of 60 HBV-ACLF patients were enrolled in this study. The observation group, comprising 30 patients, received DPMAES treatment, while the control group underwent PE treatment. We compared the efficacy changes between the two groups post-treatment. A total of 55 HBV-ACLF patients who completed the study were analyzed, Patients treated with DPMAES showed significant improvements in clinical outcomes. After DPMAES treatment, HBV-ACLF patients exhibited notably 90 day survival rate increased by 18% compared to those in the PE group. Moreover, total bilirubin levels decreased markedly, albumin and platelet levels increased compared to the PE group. After DPMAES treatment, the patient showed a significant decrease in inflammatory cytokine IL-6 (t = 5.046, P < 0.001) and a significant decrease in procalcitonin (t = 4.66, P < 0.001). DPMAES was more effective than PE in rapidly reducing TBiL, improving coagulation function and mitigating cytokine storm. It maintained platelet stability more effectively while minimizing albumin consumption to a greater extent, significantly improved 90-day survival.Trial registration: Chinese Clinical Trial Registry, ChiCTR2300076117.
Funder
The project of Science and Technology Department of Shaanxi Province
The project of Ankang Science and Technology Bureau
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Yang, F. J. et al. Research advances in diagnosis and treatment of liver failure in 2016. Chin. J. Hepatol. 25(2), 94–99 (2017).
2. Gu, W. Y. et al. Acute-on-chronic liver failure in China: Rationale for developing a patient registry and baseline characteristics. Am. J. Epidemiol. 187(9), 1829–1839 (2018).
3. Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe; Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association, Li Lanjuan, Han Tao. Guideline for diagnosis and treatment of liver failure. J. Pract. Hepatol. 22(2), 164–171 (2019).
4. Bajaj, J. S. et al. Acute-on-chronic liver failure clinical guidelines. Am. J. Gastroenterol. 117(2), 225–252 (2022).
5. Sarin, S. K. et al. Acute-on-chronic liver failure: Consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol. Int. 8(4), 453–471 (2014).